RFK Jr. Defends Makary, Claims Pharma ‘Owns’ Congress and Media

Why It Matters

The exchange underscores growing political pressure on the FDA and the stakes for biotech firms whose trial designs clash with regulator expectations, affecting investment and innovation pipelines.

Key Takeaways

• RFK Jr. backs FDA, citing 67 drug approvals under his tenure
• Replimune's RP1 rejected for using single‑arm trial instead of randomization
• BMO analysts support FDA decision, warning against hopeful resubmissions
• Kennedy claims pharma controls Congress and media, influencing FDA criticism
• CDC appoints Erica Schwartz amid rapid leadership turnover

Pulse Analysis

The hearing highlighted a familiar tension between regulators and powerful industry lobbyists. By invoking his family’s public‑health legacy, RFK Jr. framed the FDA’s recent actions as a bulwark against a pharmaceutical sector he says dominates Congress and the media. This narrative seeks to restore confidence in the agency’s independence, but it also signals that future policy debates may be increasingly politicized, with lawmakers and senior officials weighing industry influence alongside scientific merit.

Replimune’s RP1 case illustrates how trial design can become a decisive regulatory hurdle. The company pursued a single‑arm study, arguing that the therapy’s oncolytic effect was evident without a control group. FDA reviewers, however, demanded a randomized trial to isolate the drug’s impact from concurrent chemotherapy. The rejection forces Replimune to cut staff and scale back U.S. manufacturing, a stark reminder that biotech firms must align early with regulator expectations to preserve capital and pipeline momentum.

Beyond this single dispute, the broader approval landscape remains under scrutiny. While Kennedy touted 67 approvals, FDA data show 46 novel drugs and 21 biologics cleared in 2025, a modest rise from 2023’s 75 total. Discrepancies in reported figures can affect market perception and investor confidence. As the FDA navigates heightened political scrutiny and industry pressure, its ability to maintain transparent, data‑driven decision‑making will be critical for sustaining innovation pipelines and ensuring public trust in America’s drug‑approval system.